ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • ACR Convergence 2026
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • My Favorites
    • View & print my favorites
  • Search

Home » Meeting Abstracts » ACR Convergence 2026

Abstract Number: 1035

A Human Joint-on-a-Chip Platform Reveals Anti-inflammatory Effects of Cytokine-Rich Autologous Serum Derived from Patients with Rheumatoid Arthritis

Clara Eyre Olmos1, Ester Planas Rigol2, Joan Marc Cabot Canyelles2, Germà Julià Agulló3, Noemí De Luna Salvà4, Antonio D Gomez Centeno3, María García Manrique De Lara5, Menna Rusiñol González3, Alba Garcia Pinilla3, Cristina Piqué Menéndez3, Montserrat Cabanillas Paredes3, Clara Feliu Hernàndez3, Anna Carreras-Nolla3, Albert Rodrigo-Parés6, Diego Fuentes Palacios3, Ester Saus Martínez6, Sonia Montero Molina4, Núria Noguera Ferrer7, Júlia Dulsat Mas4, Àlex Arqué Corredor8, Joan Calvet Fontova3 and Eduard Graell Martín3

Affiliations: 1Hospital Parc Tauli, Barcelona, Spain, 2Leitat managing technologies, Terrassa, Spain, 3Hospital Parc Tauli, Sabadell, Spain, 4Leitat technologic center, Barcelona, Spain, 5Hospital Parc Tauli, Sabadell, Catalonia, Spain, 6Hospital Parc Tauli, Sabadell, 7Tecnologia Regenerativa Qrem S.L, Barcelona, Spain, 8Tecnologia Regenerativa Qrem S.L., Barcelona, Spain

Share on X (Twitter) Share on Facebook Share on LinkedIn Share on Email
Print

Meeting: ACR Convergence 2026

Keywords: Inflammation, rheumatoid arthritis, Synovitis, Tissue Engineering, Tumor necrosis factor (TNF)

Session Information

Date: Monday, November 9, 2026

Title: (1035-1049) Rheumatoid Arthritis - Translational Models and Mechanisms Poster B

Session Type: Poster Session B

Session Time: 10:30AM-12:30PM

Background/Purpose: Rheumatoid arthritis (RA) is characterized by synovial inflammation and joint damage. Cytokine-rich autologous serum (ACRS) is used in regenerative musculoskeletal approaches, but its anti-inflammatory activity in RA is unclear. Human organ-on-a-chip systems may model joint tissue responses and screen patient-derived interventions. We aimed to validate two human joint-on-a-chip platforms, comprising cartilage-on-a-chip and synovium-on-a-chip models, to assess the safety and anti-inflammatory effects of RA-derived ACRS under basal and TNFα-stimulated conditions

Methods: ACRS samples were obtained from a parent RA cohort stratified by age at onset, serostatus, and disease activity. For joint-on-a-chip experiments, samples from 12 seropositive patientsrepresenting 4 phenotypes were tested: elderly-onset RA in remission, elderly-onset inflammatory RA, young-onset RA in remission, and young-onset inflammatory RA (3 patients/group). Human cartilage-on-a-chip and synovium-on-a-chip models were generated in a microfluidic device using human chondrocytes and synoviocytes under basal and TNFα-stimulated conditions (Figure 1). ACRS was tested in both models and compared with glucocorticoids. Safety was assessed by bright-field microscopy and Alamar Blue assays. Anti-inflammatory effects were assessed through IL-6 quantification by ELISA. Group comparisons used t tests for statistical analysis. 

Results: ACRS did not induce cytotoxicity in either cartilage-on-a-chip or synovium-on-a-chip models. Under TNFα stimulation, ACRS reduced IL-6 secretion in cartilage-on-a-chip when derivedfrom elderly-onset RA in remission, young-onset RA in remission, and young-onset inflammatory RA (all p < 0.05), with effects comparable to glucocorticoids (Figure 2A). In synovium-on-a-chip, ACRS from elderly-onset and young-onset RA in remission prevented TNFα-induced IL-6 upregulation (p < 0.05), whereas glucocorticoids did not show a significant anti-inflammatory effect in this model (Figure 2B). Under basal conditions, ACRS did not trigger inflammatory responses, supporting an in vitro safety profile (Figure 2A-B).

Conclusion: Human cartilage-on-a-chip and synovium-on-a-chip platforms enabled the evaluation of RA patient-derived ACRS in biologically relevant inflammatory environments. ACRS showed anin vitro safety profile and reduced TNFα-induced IL-6 secretion in a tissue- and donor phenotype-dependent manner, with differential effects compared with glucocorticoids. Thesefindings support joint-on-a-chip systems as translational platforms for preclinical therapeutic screening and provide a framework for developing personalized anti-inflammatory and regenerative strategies in RA. Larger studies with expanded samples and additional molecular readouts are warranted. 

Supporting image 1Figure 1A. Cell culture configuration in the Joint-on-a-Chip model. Figure 1B. Long-term perfusion and cell monitoring in the Joint-on-a-Chip. Figure 1C. Cell viability assessment in the CoC and SoC models using Alamar Blue.

Supporting image 2Figure 2A. Cartilage-on-a-chip model used to study the safety and efficacy of ACRS treatments. Representative bright-field microscopy images are shown in the upper panel. Cell viability assessed by Alamar Blue assay is presented in the lower left panel. IL-6 ELISA results are shown in the lower right panel. Standard deviation was calculated for each group and is displayed in the graphs. Statistical analysis was performed using a t-test. * p =≤ 0.05 comparing non-senescent (untreated) vs senescent (TNFα). # p =≤ 0.05 comparing senescent (TNFα) vs corticosteroid- and ACRS-treated groups (purple). Figure 2B. Synovium-on-a-chip model used to study the safety and efficacy of ACRS treatments. Representative bright-field microscopy images are shown in the upper panel. Cell viability assessed by Alamar Blue assay is presented in the lower left panel. IL-6 ELISA results are shown in the lower right panel. Standard deviation was calculated for each group and is displayed in the graphs. Statistical analysis was performed using a t-test. * p =≤ 0.05 comparing non-senescent (untreated) vs senescent (TNFα). # p =≤ 0.05 comparing senescent (TNFα) vs corticosteroid- and ACRS-treated groups (purple).


Disclosures: C. Eyre Olmos: None; E. Planas Rigol: None; J. Cabot Canyelles: None; G. Julià Agulló: None; N. De Luna Salvà: None; A. Gomez Centeno: None; M. García Manrique De Lara: None; M. Rusiñol González: None; A. Garcia Pinilla: None; C. Piqué Menéndez: None; M. Cabanillas Paredes: None; C. Feliu Hernàndez: None; A. Carreras-Nolla: None; A. Rodrigo-Parés: None; D. Fuentes Palacios: None; E. Saus Martínez: None; S. Montero Molina: None; N. Noguera Ferrer: None; J. Dulsat Mas: None; À. Arqué Corredor: None; J. Calvet Fontova: None; E. Graell Martín: None.

To cite this abstract in AMA style:

Eyre Olmos C, Planas Rigol E, Cabot Canyelles J, Julià Agulló G, De Luna Salvà N, Gomez Centeno A, García Manrique De Lara M, Rusiñol González M, Garcia Pinilla A, Piqué Menéndez C, Cabanillas Paredes M, Feliu Hernàndez C, Carreras-Nolla A, Rodrigo-Parés A, Fuentes Palacios D, Saus Martínez E, Montero Molina S, Noguera Ferrer N, Dulsat Mas J, Arqué Corredor À, Calvet Fontova J, Graell Martín E. A Human Joint-on-a-Chip Platform Reveals Anti-inflammatory Effects of Cytokine-Rich Autologous Serum Derived from Patients with Rheumatoid Arthritis [abstract]. Arthritis Rheumatol. 2026; 78 (suppl 9). https://acrabstracts.org/abstract/a-human-joint-on-a-chip-platform-reveals-anti-inflammatory-effects-of-cytokine-rich-autologous-serum-derived-from-patients-with-rheumatoid-arthritis/. Accessed .

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-human-joint-on-a-chip-platform-reveals-anti-inflammatory-effects-of-cytokine-rich-autologous-serum-derived-from-patients-with-rheumatoid-arthritis/

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology